# A Clinical Evaluation of the HYDRA Self Expanding Transcatheter Aortic Valve

Study · id `cardio:ct-nct02434263` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02434263](<https://clinicaltrials.gov/study/NCT02434263>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02434263

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 165 participants.

## Technical summary

Registry record NCT02434263. Allocation not applicable; no masking; primary purpose treatment. Start 2015-08-13 (actual); primary completion 2022-07 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 165 participants (planned count; ClinicalTrials.gov record NCT02434263, source copy `cardio:ctgov-nct02434263-2021-10-19`, retrieved 2026-10-26)
- Started: 2015-08-13 (actual) (ClinicalTrials.gov record NCT02434263, source copy `cardio:ctgov-nct02434263-2021-10-19`, retrieved 2026-10-26)
- Primary completion: 2022-07 (anticipated) (ClinicalTrials.gov record NCT02434263, source copy `cardio:ctgov-nct02434263-2021-10-19`, retrieved 2026-10-26)
- Completion: 2025-07 (anticipated) (ClinicalTrials.gov record NCT02434263, source copy `cardio:ctgov-nct02434263-2021-10-19`, retrieved 2026-10-26)
- Countries: Greece; Hong Kong SAR China; Lithuania; New Zealand; Poland; Thailand (ClinicalTrials.gov record NCT02434263, source copy `cardio:ctgov-nct02434263-2021-10-19`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02434263-2021-10-19`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Clinical Evaluation of the HYDRA Self Expanding Transcatheter Aortic Valve
- Condition: Aortic Valve Stenosis
- Intervention (Device): Hydra TAVI
- Lead sponsor: Vascular Innovations Co. Ltd.
- Lead sponsor class: INDUSTRY
- Collaborator: MedPass International
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Aortic stenosis (`cardio:aortic-stenosis`)
- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)

## Provenance

Content hash: fa049d533e8d2684ffad0e580b8e2362c290a6cef574a6c03f2d7ad4ab4a68db
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
